• 1
    Kurland LT, Hauser WA, Ferguson RH, Holley KE. Epidemiologic features of diffuse connective tissue disorders in Rochester Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc 1969; 44: 64963.
  • 2
    Medsger TA Jr, Masi AT. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 1971; 74: 71421.
  • 3
    Medsger TA Jr, Masi AT. The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. J Chronic Dis 1978; 31: 7385.
  • 4
    Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue disease in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985; 60: 10513.
  • 5
    Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 9981006.
  • 6
    Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr. Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum 1997; 40: 4415.
  • 7
    Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 1996; 22: 75164.
  • 8
    Medsger TA Jr, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chron Dis 1963; 26: 64760.
  • 9
    Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 36976.
  • 10
    Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15: 27683.
  • 11
    Silman AJ. Mortality from scleroderma in England and Wales 1968-1985. Ann Rheum Dis 1991; 50: 956.
  • 12
    Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 40313.
  • 13
    Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82: 13948.
  • 14
    Kaburaki J, Lee CC, Kuwana M, Tojo T, Ikeda Y, Takano M, et al. Initial predictors of survival in patients with systemic sclerosis (scleroderma). Keio J Med 1992; 41: 1415.
  • 15
    Bond C, Pile KD, McNeil JD, Ahern MJ, Smith MD, Cleland LG, et al. South Australian Scleroderma Register: analysis of deceased patients. Pathology 1998; 30: 38690.
  • 16
    Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28: 24549.
  • 17
    Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 15467.
  • 18
    Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 13953.
  • 19
    Silman AJ. Scleroderma: demographics and survival. J Rheumatol Suppl 1997; 48: 5861.
  • 20
    Jones MD, Castillo LA, Hopkins CA, AaronWS, editors. St. Anthony's ICD-9-CM code book for physician payment. 5th ed. Reston (VA): St. Anthony Publishing; 1996.
  • 21
    Preliminary criteria for the classification of systemic sclerosis (scleroderma): Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 58190.
  • 22
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 23
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 24
    Schottenfeld D, Burns CJ, Gillespie BW, Laing TJ, Mayes MD, Heeringa SG, et al. The design of a population-based case-control study of systemic sclerosis (scleroderma): commentary on the University of Michigan study. J Clin Epidemiol 1995; 48: 5836.
  • 25
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 26
    Office of the State Registrar and Center for Health Statistics. Michigan Health Statistics. Lansing: Michigan Department of Public Health; 1993.
  • 27
    Cox DR. Regression models and life tables [with discussion]. J Royal Stat Soc B 1972; 74: 187220.
  • 28
    Lawless JF. Statistical models and methods for lifetime data. New York: John Wiley & Sons; 1982.
  • 29
    Wittes JT, Colton T, Sidel VW. Capture-recapture methods for assessing the completeness of case ascertainment when using multiple information sources. J Chron Dis 1974; 27: 2536.
  • 30
    Hook EB, Regal RR. The value of capture-recapture methods even for apparent exhaustive surveys: the need for adjustment for source of ascertainment intersection in attempted complete prevalence studies. Am J Epidemiol 1992; 135: 10607.
  • 31
    Hook EB, Regal RR. Accuracy of alternative approaches to capture-recapture estimates of disease frequency: internal validity analysis of data from five sources. Am J Epidemiol 2000; 152: 7719.
  • 32
    Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH Jr, Burns CJ, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 40: 73442.
  • 33
    Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30: 33246.
  • 34
    Silman A, Jannini S, Symmons D, Bacon P. An epidemiologic study of scleroderma in the West Midlands. Br J Rheumatol 1988; 27: 28690.
  • 35
    Tamaki T, Mori S, Takehara K. Epidemiologic study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991; 283: 36671.
  • 36
    Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland: a nationwide epidemiological study. Ann Rheum Dis 1994; 53: 5025.
  • 37
    Roberts-Thomson PJ, Jones M, Hakendorf P, Dharmapatni AA, Walker JG, MacFarlane JG, et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J 2001; 31: 2209.
  • 38
    Englert H, Small-McMahon J, Davis K, O'Connor H, Chambers P, Brooks P. Systemic sclerosis prevalence and mortality in Sydney 1974-1988. Aust N Z J Med 1999; 29: 4250.
  • 39
    Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 1996; 39: 136270.
  • 40
    Tan FK, Stivers DN, Arnett FC, Chakraborty R, Howard R, Reveille JD. HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tissue Antigens 1999; 53: 7480.